Part of Dana-Farber Cancer Institute and affiliated with Harvard Medical School, the Belfer Institute is built upon a tradition of research excellence and a history of medical innovation. Our scientists are leaders in their fields and our organized and integrated research teams leverage a broad network of research centers of excellence. As a result, we are at the forefront of developing the next generation of cancer therapies. The Belfer Institute recently named two new scientific co-directors and a head of research, adding to its world-class team and continuing to grow its expertise.
In the News
Poster presentation, PDx Platform of High Grade Serous Ovarian Cancer, at the 2014 AACR General Meeting in San Diego by Sangeetha Palakurthi PhD, Head of Cancer Biology and Pharmacology.
Oral presentation, Serial monitoring of EGFR mutations in plasma NSCLC patients by ddPCR, at the 2014 AACR General Meeting in San Diego by Cloud Paweletz PhD, Head of Translational Research Lab.
Findings from the Translational Research Lab within the Belfer Institute demonstrate that circulating DNA from non-invasive plasma samples is a promising biomarker to monitor response and predict resistance in the clinic.
Belfer scientists collaborate with W. Kaelin MD , to demonstrate that the Ikaros family of transcription factors are key downstream mediators of the efficacy of thalidomide-like drugs.